Network Version
T0070907 Data Sheet
| Product Name: | T0070907 |
 |
|---|---|---|
| CAS No.: | 313516-66-4 | |
| Cat. No.: | HY-13202 | |
| MWt: | 277.66 | |
| Formula: | C12H8ClN3O3 | |
| Purity : | >98% | |
| Solubility: | DMSO : 62.5 mg/mL (225.10 mM; ultrasonic and warming and heat to 60°C); H2O : 1.1 mg/mL (3.96 mM; Need ultrasonic) | |
| Mechanisms: | Target: Cancer | |
| Biological Activity: | ||
| T0070907 is a potent PPARγ antagonist with a Ki of 1 nM. IC50 & Target: Ki: 1 nM (PPARγ), 1.8 μM (PPARδ), 0.85 μM (PPARα)[4] In Vitro: T0070907 (50 μM) pre-treatment impairs repair of IR-induced DNA DSBs in both ME-180 and SiHa cells treated with irradiated (4 Gy). T0070907 (0-50 μM) significantly decreases the levels of DNA-PKcs and RAD51 proteins in ME-180 and SiHa cells[1]. T0070907 (50 μM) treatment reduces the levels of α- and β-tubulin protein in a time-dependent manner, decreases the synthesis of DNA, and prevents the radiation-induced alterations in the cell cycle regulatory proteins of ME180 and SiHa cells[2]. T0070907 (10 µM) has cytotoxicity in an adipocyte-specific and PPARγ-independent manner. T0070907 increases oxidative stress in immature adipocytes[3]. T0070907 (1 μM) blocks the induction of adipogenesis by various treatments of the adipogenic cell line 3T3-L1. T0070907 covalently modifies PPAR on cysteine 313 in helix 3 of human PPAR 2[4]. | ||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com